How to Prepare Registration Dossiers for Overseas Rehabilitation Equipment Registration

Executive Summary

To prepare registration dossiers for rehabilitation equipment overseas, manufacturers must first determine whether the target market regulates the product as a medical device, then establish the risk classification and registration pathway. Avoid simply translating NMPA, CE, or FDA files and submitting them directly. Core dossier components include technical documentation, a risk management report, performance verification and test reports, clinical evaluation or clinical evidence, labels and instructions for use, and an ISO 13485 quality management system certificate. GHWP member countries, Southeast Asia, the Middle East, and Latin America generally accept a CTD format based on the IMDRF core technical document structure, but local language conversion is required, and labels, authorized representatives, and document formats must be adapted to local regulations. Common risks include underestimating regulatory differences, not appointing a qualified local representative, lack of control over certificates, and missing post-market change and renewal management. Manufacturers should complete a pre-assessment and gap analysis before project initiation, prioritize reuse of recognized data, then supplement evidence that must be localized (e.g., language, standard references, local testing), and advance multi-country applications in phases to reduce duplicate document preparation and deficiency cycles.

For Chinese medical device manufacturers, a prudent approach is to first conduct product classification and dossier gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market dossiers can be reused. Target market registration typically affects technical documentation, authorized representatives, importer coordination, label language, quality system evidence, and subsequent change maintenance. If you proceed only with a “which documents to submit” mindset, you may face deficiencies or rework in model coverage, evidence chain consistency, label claims, and certificate control. AIMEILI recommends planning this issue within the context of GHWP member countries and multi-country access strategies, using a single reusable core technical file to support localization across different markets, rather than creating dossiers from scratch for each country.

Applicable Scenarios and Core Issues

Rehabilitation equipment overseas registration is a common but often underestimated undertaking for manufacturers entering international markets. This category includes physiotherapy devices, rehabilitation training equipment, walking aids, wheelchairs, massage devices, functional electrical stimulation equipment, etc. The scope is broad, and regulatory recognition varies significantly across target countries. The first question is whether the target market regulates the product as a medical device and the corresponding risk class and management category.

The core issue is not whether documents exist, but whether those documents are accepted by the target country. Many manufacturers already hold NMPA registration certificates, CE certificates, or FDA 510(k) clearances, but registration dossiers are not simple translations. Different countries impose separate requirements on technical document structure, clinical evidence, label language, authorized representatives, and post-market surveillance. Ignoring this can lead to deficiency letters or rejections after submission.

Therefore, the key to dossier preparation is to perform a systematic applicability assessment first, then localize and reorganize the evidence chain according to the target country's regulations.

Registration Decision Logic

Registration decisions should be made along five dimensions.

1. Regulatory scope: Confirm whether the product is a medical device in the target country. For example, massage pads may be classified as ordinary consumer products in some countries, while functional electrical stimulation devices are strictly regulated.

2. Risk classification: Each country has product categories based on its classification rules. ASEAN, Middle East, and Latin American countries often reference the IMDRF framework or EU rules. Classification directly determines the registration pathway, review timeline, and required clinical evidence.

3. Applicant entity: Most markets require a local registrant, importer, or authorized representative to submit the application. The manufacturer needs to identify the responsible entity and sign an agreement.

4. Reusability of existing documentation: Assess whether NMPA registration files, CE technical documentation, FDA submissions, ISO 13485 certificates, or MDSAP certificates can serve as supporting evidence, which can be referenced directly, and which must be re-issued or supplemented.

5. Localization requirements: This includes local language labels, instructions for use, differences in standard references, and the local acceptance scope of calibration or testing. Only after completing these five pre-assessment steps can the manufacturer form a concrete document checklist and timeline.

Dossier and Evidence

Registration dossiers are usually organized according to the format specified by the target country's regulatory authority. For most GHWP member countries and markets in Southeast Asia, the Middle East, and Latin America, a technical documentation summary based on a high-level architecture is now widely accepted. Manufacturers can prepare modules covering product basic information, quality management system information, product design description, performance evaluation, risk management, and clinical evaluation.

Physical and chemical performance documentation is foundational, including product technical specifications, main materials, working principles, functional modes, cleaning and disinfection methods, service life, and packaging integrity. Rehabilitation equipment often includes electrical components, so IEC 60601 series electrical safety and electromagnetic compatibility test reports are critical. If the device contains batteries, wireless modules, or sensors, additional standards requirements must be addressed.

Biocompatibility documentation applies to devices or materials that contact the body. If rehabilitation equipment includes electrode pads, massage heads, contact cushions, or straps, cytotoxicity, sensitization, and irritation assessments per ISO 10993 series are required. Reports issued by testing organizations in certain countries may be accepted, but local regulators may require reports from nationally recognized laboratories or data acceptance procedures.

Risk management report (ISO 14971) and quality system certificate (ISO 13485) are mandatory technical documents. For manufacturers with CE or FDA experience, risk analysis and usability engineering documents can often be reused, but check whether the target country has additional requirements, such as warnings and contraindications on labels being in the local language.

Clinical evaluation or clinical evidence is a challenging part of the dossier. Rehabilitation equipment is often registered based on claims of improving function or relieving symptoms, so the logical link between the user population, indications, and claimed endpoints must be demonstrated. If evidence from systematic literature reviews, clinical data, or equivalent device evaluations already exists, prioritize reuse. However, local regulations may require submission of a clinical summary or clinical trial data relevant to the target population.

Administrative documents include the local agent or authorized representative letter of authorization, declaration of conformity, certificate of free sale, and notarized or legalized copies of production licenses or ISO 13485 certificates. Manufacturers must also prepare local language versions of labels and instructions for use, ensuring not only accurate translation but also that symbols, warnings, and units of measurement comply with local regulations.

Common Mistakes

• Skipping product classification pre-assessment and preparing dossiers according to the home country's registration category, resulting in document structure and evidence volume not meeting target country requirements.
• Translating NMPA or CE Chinese reports directly into the target language and submitting them, ignoring local technical standards, testing methods, and format differences, leading reviewers to require re-issued reports.
• Inadequate clinical evidence, especially lacking sufficient justification for the target population or use environment, and substituting generic promotional descriptions for systematic literature review and risk-benefit analysis.
• Failing to appoint and confirm a qualified local agent or authorized representative at the initial project stage, then being forced to change representatives during the process, causing interruption in original submission materials, certificate control, or deficiency response.
• Label and instruction translation that does not conform to local language conventions, fails to distinguish warnings, cautions, and contraindications, or does not consider mandatory regulatory requirements for medical device symbols and formats.
• Missing post-market surveillance planning, including adverse event reporting, vigilance systems, annual updates, and change notification processes, making the registration certificate ineffective in the long term.
• Not preserving original records of the evidence chain, making it impossible to provide raw test data, risk documents, and change records during deficiency response or onsite inspection.

Manufacturer Preparation Checklist

• List target countries and priorities, and determine the regulatory scope, classification, and registration pathway for each market.
• Establish an inventory of existing registration documents, identifying which can be reused (e.g., ISO 13485 certificates, risk management reports, test reports) and which must be supplemented or localized.
• Select and confirm a local agent or authorized representative, complete the authorization letter and contract, and ensure clear arrangements for certificate control and change/renewal management.
• Prepare the technical documentation summary, product description, labels, and instructions for use in local language versions, and conduct internal regulatory review.
• Complete testing and evidence, such as electrical safety, EMC, biocompatibility, performance verification, and clinical evaluation, ensuring reports are issued by laboratories with recognized competence.
• Establish internal processes from pre-registration evidence preparation to post-registration change management, including adverse event reporting and post-market surveillance records.
• Set internal timelines and milestones for each target country, with buffer time for deficiency responses and communication with local agents.

AIMEILI Regulatory Interpretation and Business Impact

Overseas registration should be treated as an evidence package building process, not a translation task. The most common misjudgment is assuming that CE or FDA documentation is globally accepted. In reality, GHWP systems and Southeast Asian, Middle Eastern, and Latin American countries have significantly different requirements. Document structure can follow a common framework, but standard references, language, testing acceptance, and clinical evidence requirements must be re-evaluated.

A complete gap analysis before project initiation is recommended. First determine the target country's regulatory category and submission format, then compare existing documents item by item to identify which evidence is recognized and which must be supplemented. This step saves significant time and budget, as many deficiency items arise from a lack of “classification first, preparation second” approach.

Reusable documents include ISO 13485 systems, ISO 14971 risk management reports, basic test reports, and electrical safety standards reports. Documents that must be localized include label and instruction language, administrative documents required by local agents, notarized or legalized copies of certain test reports, and clinical summaries or clinical evaluations relevant to the local population.

Local agents and certificate control are foundational infrastructure for multi-country registration. Manufacturers should clarify with the local agent who holds the certificate, how changes are coordinated, and who bears renewal fees. If certificate control is delegated without constraints, subsequent product updates or entry into new countries can face obstacles.

To reduce duplicate preparation and deficiency risk in multi-country programs, adopt a master technical file plus country-specific variations strategy. Use one master technical file as the core and adjust subsidiary modules and local evidence according to each target country's requirements. This way, even if five countries are progressing simultaneously, you do not need to prepare a completely different set of materials from scratch for each.

Frequently Asked Questions

How do I determine the classification of rehabilitation equipment in a target country?

Refer to the target country's official classification rules or published classification databases, then consider product intended use, contact time, invasiveness, and whether energy is supplied. If necessary, consult a local agent or regulatory authority, but first complete the product technical description and intended use definition.

Can rehabilitation equipment be registered without clinical trial data?

Some low-risk rehabilitation equipment can support clinical evaluation through equivalent device comparison and literature data. However, medium- and high-risk rehabilitation equipment typically requires submission of a clinical trial summary or clinical trial protocol. Assess the target country's clinical evidence level requirements rather than assuming none is needed.

Will a change of local agent after registration affect the certificate?

Generally, a change of local agent or authorized representative requires submission of a change application to the local regulatory authority, along with transition documents between the old and new agents. If not notified as required, the validity of the certificate and post-market communication may be affected. Plan ahead through contracts and processes.

Can dossiers be shared for simultaneous multi-country registration?

Yes, sharing is feasible provided a master technical file structure is established. Regulatory authorities in different countries generally accept similar document modules, with differences concentrated in standard references, language, administrative documents, and clinical evaluation. Maintain a country-specific difference table for each target country to avoid repeatedly modifying the same evidence.

Continue Reading

Previous: How to Use ISO 13485 Certificate for Imaging Equipment Overseas Registration?
Next: How to Divide Responsibilities of Authorized Representative for Patient Monitoring Equipment Overseas Registration?

Recommended reading:
Can Test Reports Be Reused for Patient Monitoring Equipment Overseas Registration?
How to Prepare Performance Verification Dossier for Patient Monitoring Equipment Overseas Registration?
How to Localize Labels and Instructions for Imaging Equipment Overseas Registration?
How to Use ISO 13485 Certificate for Imaging Equipment Overseas Registration?
How to Divide Responsibilities of Authorized Representative for Patient Monitoring Equipment Overseas Registration?
How to Perform Post-Market Surveillance for Patient Monitoring Equipment Overseas Registration?

Return to FAQ Center | News & Updates | Contact AIMEILI

Content Review and Applicability Boundary

Content author: AIMEILI Regulatory Editorial Department
Professional review: AIMEILI Medical Device International Registration Project Team
Source principle: Priority is given to official regulatory agencies, international organizations, standards organizations, and public regulatory materials; industry media and project experience are used only as auxiliary reference.

Applicability boundary: This article is for preliminary understanding, documentation preparation, and project planning. It does not replace the official requirements, testing conclusions, or legal advice of the target country's regulatory authority.